Reactions to Total Dose Intravenous Infusion of Iron Dextran (Imferon)

Clay, Barbara; Rosenberg, B.; Sampson, Nanita; Samuels, S. I.
January 1965
British Medical Journal;1/2/1965, Vol. 1 Issue 5426, p29
Academic Journal
No abstract available.


Related Articles

  • Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Koutroubakis, Ioannis; Oustamanolakis, Pantelis; Karakoidas, Christos; Mantzaris, Gerassimos; Kouroumalis, Elias; Koutroubakis, Ioannis E; Mantzaris, Gerassimos J; Kouroumalis, Elias A // Digestive Diseases & Sciences;Aug2010, Vol. 55 Issue 8, p2327 

    Background: Intravenous iron has been suggested as a safe and effective treatment of anemia complicating inflammatory bowel disease (IBD). Low molecular weight (LMW) iron dextran has the ability to administer the patient's total iron requirement in a single infusion.Aims:...

  • Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia. Ricardo Friedrisch, João; Delfini Cançado, Rodolfo // Revista Brasileira de Hematologia e Hemoterapia;Nov/Dec2015, Vol. 37 Issue 6, p400 

    Nutritional iron deficiency anemia is the most common deficiency disorder, affecting more than two billion people worldwide. Oral iron supplementation is usually the first choice for the treatment of iron deficiency anemia, but in many conditions, oral iron is less than ideal mainly because of...

  • Dialysate Iron Therapy: A Potential Alternative to IV Iron Dextran.  // Kidney;Nov/Dec99, Vol. 8 Issue 6, p262 

    Evaluates the safety and efficacy of dialysate iron therapy or infusing soluble ferric pyrophosphate by dialysis, to replenish ongoing iron losses. Stabilization of maintenance dialysis patients receiving erythropoietin with maintenance intravenous (IV) iron dextran; Weekly dose of IV iron...

  • Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Auerbach, M.; Al Talib, K. // Kidney International;Mar2008, Vol. 73 Issue 5, p528 

    Serious adverse events that occur with the administration of iron dextran are due to the high molecular weight preparations. Conclusions that iron sucrose and ferric gluconate are safer than iron dextran may be premature. Published literature comparing safety profiles of available parenteral...

  • The safety of accelerated infusion versus standard rate infusion of low-molecular-weight iron dextran in patients with chronic kidney disease. Sinha, Smeeta; Chiu, Diana Y. Y.; Peebles, George; Kolakkat, Shabeer; Lamerton, Elizabeth; Fenwick, Sean; Kalra, Philip A. // Nephrology Dialysis Transplantation;Oct2009, Vol. 2 Issue 5, p432 

    The article presents a study which evaluates the safety of adopting an accelerated regimen for the administration of total dose infection (TDI) low-molecular-weight iron dextran. The results of the study show the safety of the accelerated rate of low-molecular-weight iron dextran infusion as a...

  • Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Michael, Beckie; Coyne, Daniel W; Fishbane, Steven; Folkert, Vaughn; Lynn, Robert; Nissenson, Allen R; Agarwal, Rajiv; Eschbach, Joseph W; Fadem, Stephen Z; Trout, J. Richard; Strobos, Jur; Warnock, David G; Ferrlecit Publication Committee // Kidney International;May2002, Vol. 61 Issue 5, p1830 

    Background: Parenteral iron is often required by hemodialysis patients to maintain adequate iron stores. Until recently, the only available form of intravenous iron was iron dextran, which is associated with significant adverse reactions, including anaphylaxis and death. Sodium...

  • IV Total Dose Iron: Safe, Effective, and Superior to Oral Iron.  // Kidney;Jan/Feb99, Vol. 8 Issue 1, p37 

    Presents the findings of a study which compared the efficacy of intravenous infusion of total dose iron (ITDI) with oral iron for maintenance iron therapy in peritoneal dialysis (PD) patients receiving erythropoietin (EPO). Conclusion that ITDI was effective in iron supplementation in PD...

  • Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Gupta, Ajay; Amin, Neeta B.; Besarab, Anatole; Vogel, Susan E.; Divine, George W.; Yee, Jerry; Anandan, J. V. // Kidney International;May1999, Vol. 55 Issue 5, p1891 

    Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Background. Soluble iron salts are toxic for parenteral administration because free iron catalyzes free radical generation. Pyrophosphate strongly complexes iron and enhances iron transport...

  • Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia. Hussain, Iftikhar; Bhoyroo, Jessica; Butcher, Angelia; Koch, Todd A.; He, Andy; Bregman, David B. // Anemia (20901267);2013, p1 

    Several intravenous iron complexes are available for the treatment of iron deficiency anemia (IDA). Iron dextran (DEX) is associated with an elevated risk of potentially serious anaphylactic reactions, whereas others must be administered in several small infusions to avoid labile iron reactions....

  • Acute Exacerbation of Ankylosing Spondylitis After an Iron Dextran Infusion. Cantor, Ronald I.; Downs, George E.; Abruzzo, John L. // Annals of Internal Medicine;Dec72, Vol. 77 Issue 6, p933 

    Focuses on an acute exacerbation of spondylitis developed after an intravenous infusion of iron dextran in a 49-year-old patient with known ankylosing spondylitis. Information on acute exacerbations of rheumatoid arthritis; Symptoms of the disease; Diagnosis and treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics